TD Private Client Wealth’s NovoCure NVCR Stock Holding History

TD Private Client Wealth’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-95	Closed	-$7.87K	–	1269
2022 Q1	$7.87K	Buy	+95	New	+$7K	﹤0.01%	1063
2021 Q4	–	Sell	-11	Closed	-$1.28K	–	1238
2021 Q3	$1.28K	Buy	+11	New	+$1.66K	﹤0.01%	1073

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Private Client Wealth's NVCR Position: Q2 2022 in Review

TD Private Client Wealth sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 95 shares — an estimated $7.87K sold.

TD Private Client Wealth first reported a position in NVCR in Q3 2021 and held it in 2 quarters. The position peaked at $7.87K in Q1 2022. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

TD Private Client Wealth reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
TD Private Client Wealth sold 95 NovoCure shares in Q2 2022, an estimated $7.87K.
TD Private Client Wealth first reported a position in NovoCure in Q3 2021 and held it in 2 quarters.
TD Private Client Wealth's NovoCure position peaked at $7.87K in Q1 2022.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on TD Private Client Wealth's 13F filing for Q2 2022, filed 16 Aug 2024.